Effects on the endocrine system of long-term treatment with the non-steroidal anti-androgen Casodex in patients with benign prostatic hyperplasia

1995 ◽  
Vol 75 (3) ◽  
pp. 335-340 ◽  
Author(s):  
L.M. Eri ◽  
E. Haug ◽  
K.J. Tveter
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Endocrine System ◽  
Term Treatment ◽  
Prostatic Hyperplasia ◽  
Long Term Treatment

Rational treatment of benign prostatic hyperplasia: efficacy of long-term treatment with dutasteride

2016 ◽  
Vol 18 (7) ◽  
pp. 19-21
Author(s):  
V.N. Tkachuk ◽  
◽  
S.Yu. Borovets ◽  
I.N. Tkachuk ◽  
M.M. Iziev ◽  
...  
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Term Treatment ◽  
Prostatic Hyperplasia ◽  
Rational Treatment ◽  
Long Term Treatment

Long-term Treatment of Benign Prostatic Hyperplasia with Alfuzosin: a 12-18 Month Assessment

1993 ◽  
Vol 72 (5) ◽  
pp. 615-620 ◽  
Author(s):  
A. JARDIN ◽  
H. BENSADOUN ◽  
M. C. DELAUCHE-CAVALLIER ◽  
P. ATTALI
Keyword(s):  
Benign Prostatic Hyperplasia ◽  
Term Treatment ◽  
Prostatic Hyperplasia ◽  
Long Term Treatment

Long-term dutasteride therapy in men with benign prostatic hyperplasia alters glucose and lipid profiles and increases severity of erectile dysfunction

2017 ◽  
Vol 30 (3) ◽  
Author(s):  
Abdulmaged Traish ◽  
Karim Sultan Haider ◽  
Gheorghe Doros ◽  
Ahmad Haider
Keyword(s):  
Blood Glucose ◽  
Benign Prostatic Hyperplasia ◽  
Specific Antigen ◽  
Term Treatment ◽  
Prostatic Hyperplasia ◽  
Urinary Tract Symptoms ◽  
Long Term Treatment

AbstractBackgroundDutasteride has been successfully used in treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). However, dutasteride inhibits 5α-reductase type 1 and type 2 enzymes and may compromises glucocorticoids and androgen metabolism and alters metabolic function resulting in undesirable metabolic and sexual adverse side effects.AimThe aim of this study was to investigate the long-term adverse effects of dutasteride therapy in men with BPH on: i) blood glucose, ii) glycated hemoglobin (HbAMethodsA retrospective registry study, with a cohort of 230 men aged between 47 and 68 years (mean 57.78 ± 4.81) were treated with dutasteride (0.5 mg/day) for LUTS, secondary to BPH. A second cohort of 230 men aged between 52 and 72 years (mean 62.62 ± 4.65) were treated with tamsulosin (0.4 mg). All men were followed up for 36–42 months. At intervals of 3–6 months, and at each visit, plasma glucose, HbAResultsLong-term treatment with dutasteride therapy is associated with significant improvements in LUTS, as assessed by reduction in prostate volume, IPSS and prostate specific antigen (PSA). Long-term dutasteride therapy, however, resulted in increased blood glucose, HbAConclusionOur findings suggest that long-term dutasteride therapy produces worsening of ED, reduced T levels and increased glucose, HbA

Sign in / Sign up

Export Citation Format

Share Document